Business Wire

Armis Named Leader in GigaOm Radar Report for Operational Technology (OT) Security

10.7.2023 15:00:00 EEST | Business Wire | Press release

Share

Armis, the leading asset visibility and security company, today announced that it has been named a leader in the GigaOm Radar Report for Operational Technology (OT) Security.

“We’re proud to be recognized by GigaOm as a leader in operational technology security,” said Nadir Izrael, CTO and Co-founder, Armis. “It’s critical to secure the hardware and software systems that control physical devices and the industrial processes that our society depends on. Our mission is to ensure the availability, reliability and safety of these industrial control systems by mitigating cybersecurity risks that could otherwise lead to system failures, operational disruptions or physical damages.”

Within the GigaOm Radar for OT Security, Armis is:

  • positioned in the Leaders ring, recognized for being a highly scalable platform and for the solution's strong vulnerability management features, practical AI and dynamic segmentation.
  • housed in the Innovation/Platform Play quadrant. The Innovation positioning highlights technical innovation while the Platform Play displays a broader platform focus and commitment to a comprehensive feature set.
  • recognized as a Fast Mover when evaluating strategy and pace of innovation in this forward-looking assessment plotting the current projected positioning of each vendor over a 12- to 18-month window.

“Of all the vendors we looked at, Armis provided the fastest time to value and the widest coverage. Because it’s cloud-based, Armis is also simple to manage. All these factors made it easy to choose Armis, frankly,” said Mike Towers, Chief Security and Trust Officer, Takeda Pharmaceuticals. “Thanks to Armis, we’ve already uncovered a series of potential cyber risks. Without the Armis deployment, we never would have known they existed. It has already paid for itself.”

Armis is rated exceptional in the report for its:

  • SaaS solution which serves large enterprises and manufacturers
  • AI technologies for threat detection and rendezvous capabilities which GigaOm considered differentiating and critical in this sector
  • product evaluation metrics, specifically scalability and compliance.

Additionally, Armis was recognized as the only OT vendor with FedRAMP Moderate ATO, ISO 27001, ISO 28018 Best Practices and SOC 2 Type II certifications.

“A key differentiator for Armis is its excellent knowledge base, which contains critical information about the billions of devices under its monitoring umbrella, including both the device profile and the expected behaviors of that device,” said Chris Ray, Research Analyst at GigaOm. “This solution is able to leverage that information to quickly identify unusual or abnormal conditions that legacy security tools (like an intrusion detection system, or IDS) would not be able to detect. Armis has a strong focus on healthcare, manufacturing and the public sector. From our point of view, the product complements existing OT security solutions.”

“From an overall security perspective, visibility into the manufacturing area was a big thing for us,” said Shem Stephens, Security Engineer at Colgate-Palmolive. “We needed a tool to see what our plants are doing in order to better support them in terms of their security posture— and Armis fit the bill perfectly. Our auditing team uses Armis to look into areas of opportunity at our plants. And systems engineers use Armis to see when a programmable logic controller (PLC) was last changed out. They have that information at their fingertips now. As our leadership continues to collaborate with Armis leadership, we can create these unique use cases that provide tremendous benefits for specific teams or individuals.”

To read the full GigaOm Radar Report for Operational Technology (OT) Security, please visit: https://www.armis.com/analyst-reports/gigaom-radar-for-ot-security/

For the Armis blog surrounding this report, go to: https://www.armis.com/blog/armis-named-leader-in-gigaom-radar-report-for-operational-technology-ot-security/

Learn more about Armis’ OT cybersecurity solutions and how the company is helping customers secure operational technology here: https://www.armis.com/solutions/ot-device-security/

About Armis

Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye